CN1313081C - 含有胶体二氧化硅的缬无环鸟苷片剂 - Google Patents

含有胶体二氧化硅的缬无环鸟苷片剂 Download PDF

Info

Publication number
CN1313081C
CN1313081C CNB2003101029136A CN200310102913A CN1313081C CN 1313081 C CN1313081 C CN 1313081C CN B2003101029136 A CNB2003101029136 A CN B2003101029136A CN 200310102913 A CN200310102913 A CN 200310102913A CN 1313081 C CN1313081 C CN 1313081C
Authority
CN
China
Prior art keywords
tablet
valacv
filler
silica sol
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003101029136A
Other languages
English (en)
Chinese (zh)
Other versions
CN1494898A (zh
Inventor
B·H·卡尔特尔
L·G·蒂尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1313081(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of CN1494898A publication Critical patent/CN1494898A/zh
Application granted granted Critical
Publication of CN1313081C publication Critical patent/CN1313081C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB2003101029136A 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂 Expired - Fee Related CN1313081C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9501127.6 1995-01-20
GBGB9501127.6A GB9501127D0 (en) 1995-01-20 1995-01-20 Tablet

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN96192661A Division CN1131026C (zh) 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂

Publications (2)

Publication Number Publication Date
CN1494898A CN1494898A (zh) 2004-05-12
CN1313081C true CN1313081C (zh) 2007-05-02

Family

ID=10768317

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2003101029136A Expired - Fee Related CN1313081C (zh) 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂
CN96192661A Expired - Fee Related CN1131026C (zh) 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN96192661A Expired - Fee Related CN1131026C (zh) 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂

Country Status (38)

Country Link
US (1) US5879706A (enExample)
EP (1) EP0806943B1 (enExample)
JP (1) JP3350055B2 (enExample)
KR (1) KR100412298B1 (enExample)
CN (2) CN1313081C (enExample)
AP (1) AP666A (enExample)
AT (1) ATE190483T1 (enExample)
AU (1) AU710823B2 (enExample)
BG (1) BG63187B1 (enExample)
BR (1) BR9606769A (enExample)
CA (1) CA2210891C (enExample)
CY (1) CY2182B1 (enExample)
CZ (1) CZ296514B6 (enExample)
DE (1) DE69607146T2 (enExample)
DK (1) DK0806943T3 (enExample)
EA (1) EA000276B1 (enExample)
EE (1) EE03336B1 (enExample)
ES (1) ES2145425T3 (enExample)
FI (1) FI119722B (enExample)
GB (1) GB9501127D0 (enExample)
GE (1) GEP20022752B (enExample)
GR (1) GR3033677T3 (enExample)
HU (1) HU226131B1 (enExample)
IL (1) IL116830A (enExample)
IN (1) IN181318B (enExample)
MY (1) MY126346A (enExample)
NO (1) NO311488B1 (enExample)
NZ (1) NZ298846A (enExample)
OA (1) OA10500A (enExample)
PL (1) PL185307B1 (enExample)
PT (1) PT806943E (enExample)
RO (1) RO118175B1 (enExample)
SK (1) SK282030B6 (enExample)
TR (1) TR199700657T1 (enExample)
UA (1) UA68325C2 (enExample)
UY (2) UY25774A1 (enExample)
WO (1) WO1996022082A1 (enExample)
ZA (1) ZA96448B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
HUP0105463A3 (en) * 1998-12-18 2003-03-28 Abbott Lab Controlled release formulation of divalproex sodium
GB0010446D0 (en) 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ　グループ　リミテッド 塩酸バラシクロビルの無水結晶形
US6849737B2 (en) * 2001-11-14 2005-02-01 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
ES2270172T3 (es) * 2002-10-16 2007-04-01 Teva Pharmaceutical Industries Ltd. Procedimiento para reducir alcoholes residuales en hidrocloruro de valaciclovir cristalino.
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
US20050085491A1 (en) * 2003-06-02 2005-04-21 Igor Lifshitz Novel crystalline forms of valacyclovir hydrochloride
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
ES2246034T3 (es) * 2003-12-09 2006-02-01 Helm Ag Formulacion farmaceutica de valaciclovir.
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (ko) 2004-12-06 2012-02-22 에스케이케미칼주식회사 안정성이 개선된 말레인산 암로디핀 약제 조성물
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
US7846937B2 (en) * 2005-05-25 2010-12-07 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
WO2007128350A1 (en) * 2006-05-10 2007-11-15 Evonik Degussa Gmbh Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
RU2446800C2 (ru) * 2006-05-31 2012-04-10 Вертекс Фармасьютикалз Инкорпорейтед Препаративные формы с контролируемым высвобождением
EP2040684B1 (en) * 2006-07-11 2013-01-23 LEK Pharmaceuticals d.d. Multiple unit tablets
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
MX2011009440A (es) * 2009-03-13 2011-11-04 Toyama Chemical Co Ltd Tableta y polvo granulado que contiene 6-fluoro-3-hidroxi-2-pirazi ncarboxamida.
CH703348A1 (de) * 2010-06-29 2011-12-30 Mepha Gmbh Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.
GB2515486A (en) * 2013-06-24 2014-12-31 Kraft Foods R & D Inc Soluble Beverage Ingredients
KR101497508B1 (ko) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (zh) * 2019-07-30 2023-02-10 珠海润都制药股份有限公司 一种盐酸伐昔洛韦片及其制备方法
WO2021245519A1 (en) * 2020-06-01 2021-12-09 Shilpa Medicare Limited Fast dispersible pharmaceutical composition comprising capecitabine
CA3195598A1 (en) * 2020-12-01 2022-06-09 Seok Cheol YOO Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same
WO2024047094A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308065A2 (en) * 1987-08-15 1989-03-22 The Wellcome Foundation Limited Therapeutic nucleosides
WO1995005179A1 (en) * 1993-08-18 1995-02-23 The Wellcome Foundation Limited Therapeutic combination containing an anti-varicella zoster virus compound and lamotrigine
CN1131026C (zh) * 1995-01-20 2003-12-17 惠尔康基金会集团公司 含有胶体二氧化硅的缬无环鸟苷片剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
ES2052911T3 (es) * 1988-05-04 1994-07-16 Smith Kline French Lab Tableta masticable.
FI20021701L (fi) * 1991-01-30 2002-09-24 Wellcome Found Veteen dispergoituvia tabletteja
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308065A2 (en) * 1987-08-15 1989-03-22 The Wellcome Foundation Limited Therapeutic nucleosides
WO1995005179A1 (en) * 1993-08-18 1995-02-23 The Wellcome Foundation Limited Therapeutic combination containing an anti-varicella zoster virus compound and lamotrigine
CN1131026C (zh) * 1995-01-20 2003-12-17 惠尔康基金会集团公司 含有胶体二氧化硅的缬无环鸟苷片剂

Also Published As

Publication number Publication date
CA2210891A1 (en) 1996-07-25
CN1131026C (zh) 2003-12-17
EE03336B1 (et) 2001-02-15
PL321361A1 (en) 1997-12-08
DE69607146D1 (de) 2000-04-20
DK0806943T3 (da) 2000-07-24
JPH10512564A (ja) 1998-12-02
SK96497A3 (en) 1998-01-14
IL116830A0 (en) 1996-05-14
WO1996022082A1 (en) 1996-07-25
AU4453496A (en) 1996-08-07
HUP9801872A2 (hu) 1999-10-28
NO973327L (no) 1997-09-16
HUP9801872A3 (en) 2001-02-28
NZ298846A (en) 1998-06-26
NO973327D0 (no) 1997-07-18
BG63187B1 (bg) 2001-06-29
IL116830A (en) 2000-02-29
US5879706A (en) 1999-03-09
FI119722B (fi) 2009-02-27
BG101831A (en) 1998-04-30
KR19980701524A (ko) 1998-05-15
AP666A (en) 1998-08-24
FI973062L (fi) 1997-09-18
MY126346A (en) 2006-09-29
EP0806943A1 (en) 1997-11-19
PL185307B1 (pl) 2003-04-30
AU710823B2 (en) 1999-09-30
ATE190483T1 (de) 2000-04-15
OA10500A (en) 2002-04-10
CZ296514B6 (cs) 2006-03-15
GB9501127D0 (en) 1995-03-08
CY2182B1 (en) 2002-08-23
EA000276B1 (ru) 1999-02-25
HU226131B1 (en) 2008-05-28
NO311488B1 (no) 2001-12-03
CN1179100A (zh) 1998-04-15
CZ229297A3 (cs) 1998-02-18
CN1494898A (zh) 2004-05-12
UA68325C2 (en) 2004-08-16
EP0806943B1 (en) 2000-03-15
EA199700123A1 (ru) 1997-12-30
UY25774A1 (es) 2000-10-31
CA2210891C (en) 2009-05-19
ZA96448B (en) 1996-08-07
SK282030B6 (sk) 2001-10-08
PT806943E (pt) 2000-08-31
HK1002851A1 (en) 1998-09-25
DE69607146T2 (de) 2000-09-21
JP3350055B2 (ja) 2002-11-25
GEP20022752B (en) 2002-08-26
RO118175B1 (ro) 2003-03-28
MX9705459A (es) 1997-10-31
ES2145425T3 (es) 2000-07-01
IN181318B (enExample) 1998-05-09
TR199700657T1 (xx) 1998-02-21
GR3033677T3 (en) 2000-10-31
BR9606769A (pt) 1997-12-30
FI973062A0 (fi) 1997-07-18
AP9701057A0 (en) 1997-10-31
UY25778A1 (es) 2000-08-21
KR100412298B1 (ko) 2004-04-21

Similar Documents

Publication Publication Date Title
CN1313081C (zh) 含有胶体二氧化硅的缬无环鸟苷片剂
CN1049893C (zh) 缬无环鸟苷盐酸盐及其制法和其制药应用
TWI321475B (en) Novel pharmaceutical formulations of modafinil
CN1297274C (zh) 药物组合物
JP2015091882A (ja) 被覆錠剤製剤
CN1240132A (zh) 控制释放制剂
CN88101104A (zh) 药物片剂、药物粒剂及其制备方法
CN87105828A (zh) 苏灵大或苏灵大钠和碱的速效组合物
JP4097698B2 (ja) 一日一回の投与による陰部ヘルペス治療用医薬の製造のためのバラシクロビールの使用
CN101073563A (zh) 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片
CA2498506A1 (en) Novel pharmaceutical formulations of modafinil
CN1612873A (zh) 5－(4－(2－(n－甲基－n－(2－吡啶基)氨基)乙氧基)苄基)噻唑烷－2,4－二酮以及包含该化合物的药物组合物
CN1660105A (zh) 含有替加氟、吉莫斯特和氧嗪酸钾的口腔崩解片
CN101066267A (zh) 一种含有阿立哌唑微晶的固体口服药物组合物
CN106955273B (zh) 一种含有钠-葡萄糖协同转运蛋白2抑制剂的药物组合物
CN1281272C (zh) 干扰素阴道泡腾胶囊及制备方法
MXPA97005459A (en) Valaciclovir tablets containing silicon dioxide color
HK1002851B (en) Valaciclovir tablets containing colloidal silicon dioxide
CN1642549A (zh) 包含纳米颗粒形状的2－(4－乙氧基－苯基)－3－(4－甲磺酰基－苯基)－吡唑并[1, 5－b]哒嗪的药物组合物
CN1596951A (zh) 黄柏分散片及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070502

Termination date: 20110119